Cargando…
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
Relapsed/refractory acute myeloid leukemia (AML) patients generally have a dismal prognosis and the treatment remains challenging. Due to the expression of CD7 on 30% AML and not on normal myeloid and erythroid cells, CD7 is an attractive target for immunotherapy of AML. CD7-targeted CAR T-cells had...
Autores principales: | Cao, Xuanqi, Dai, Haiping, Cui, Qingya, Li, Zheng, Shen, Wenhong, Pan, Jinlan, Shen, Hongjie, Ma, Qinfen, Li, Mengyun, Chen, Sifan, Chen, Juncheng, Zhu, Xiaming, Meng, Huimin, Yang, Lin, Wu, Depei, Tang, Xiaowen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523980/ https://www.ncbi.nlm.nih.gov/pubmed/36175988 http://dx.doi.org/10.1186/s40164-022-00318-6 |
Ejemplares similares
-
P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: LI, Tingting, et al.
Publicado: (2023) -
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Cui, Qingya, et al.
Publicado: (2021) -
Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy
por: Gu, Jingxian, et al.
Publicado: (2022) -
P378: CHEMO-FREE TREATMENT OF VAF INDUCE A EARLY AND DEEP MOLECULAR RESPONSEIN IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA: A PROSPECTIVE, SINGLE ARM, PHASE II STUDY
por: LI, Mengyun, et al.
Publicado: (2023) -
Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase
por: Cui, Qingya, et al.
Publicado: (2022)